In this open labeled 8-week trial 40 patients with symptomatic SAR currently using Olopatadine 1330 mgc/nostril BID or Mometasone furoate, 100 mcg/nostril QD were randomized to receive the combination Olopatadine 1330 mcg/nostril BID + Mometasone, 100 mcg/nostril QD. The end points of the trial include: rhinomanometry, nasal symptom score (composite score of nasal congestion, rhinorrhea, sneezing post nasal drip and itching) and flexible rhinopharyngolaryngoscopy examination.
Mean efficacy measurements at the end of the 8-week trial revealed significant improvements in all parameters examined in the combination treatment group as compared to baseline measurements.
In conclusion, the combination nasal Olopatadine plus nasal Mometasone is more effective than monothereapy nasal Olopatadine or nasal Mometasone. It appears that in the combination treatment Olopatadine and Mometasone, the primary end points (rhinomanometry and symptom scores) are significantly improved.